JavaScript is Disabled
Your browser's JavaScript functionality is disabled. It has to be enabled to use this function of ConfTool.
Here you can find information on how to enable JavaScript
If you have any problems, please contact the organizers at parasitologycommunicator@gmail.com.

Conference Agenda

Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).

Daily Overview

Session

CP5.1: Immunology 1 - 10 min talks
Location: Lecture Theatre 2
Session Chair: Danielle Stanisic, Institute for Biomedicine and Glycomics, Griffith University
Session Chair: Hannah Siddle, The University of Queensland

Presentation 2

Naturally acquired IgG and IgM responses to Plasmodium vivax and association of protection from clinical malaria

Janani Karunarathne^1,2, Ivo Mueller^1,2, Rhea Longley^1,2,3

1: Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia; 2: Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia; 3: Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

Plasmodium vivax is the most widespread Plasmodium species causing human malaria, remains a major global health risk. Effective interventions against P. vivax remain challenging due to its distinct biology. Although vaccines exist for Plasmodium falciparum, P. vivax lacks a licensed vaccine and has few candidates in clinical trials. Naturally acquired clinical immunity to malaria, driven by antibody responses that develop through repeated exposure in endemic areas, provides promising insights for vaccine development. This study evaluated whether IgG and IgM responses to P. vivax antigens are associated with protection against clinical malaria across transmission settings. Antibody responses to 61 antigens were simultaneously measured using the Luminex INTELLIFLEX platform in longitudinal cohorts from low transmission settings (Brazil, n = 258; Thailand n = 70) and a high transmission setting (Papua New Guinea, n = 184), where participants were followed over time for clinical malaria episodes used in the data analysis. The study shows that high IgG levels against RBP2b, EBPII, MSP3a, MSP5, RBP2a, CyRPA, RIPR, Pv-fam-a (PVX_090265), MSP7, RAMA, RBP2c-non-binding region and stAR related lipid transfer protein are strongly associated with protection from clinical malaria across all three cohorts. Overall, this study has identified both well-studied vaccine candidates and underexplored candidates.